American Society of Hirudotherapy

Hand-Arm Vibration Syndrome (Investigational Adjunct)

Investigational adjunct for vascular and neurosensory components of hand-arm vibration syndrome; cessation of vibration exposure, smoking cessation, calcium channel blockers for vascular component, and gabapentinoids for neurosensory pain remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for hand-arm vibration syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational, with no identified clinical-study support.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for HAVS was identified in PubMed or Europe PMC. Stockholm Workshop staging guides severity. The single most important intervention is removal from vibration exposure; without that, no other therapy can halt progression. Smoking cessation, cold avoidance, calcium channel blockers (typically nifedipine) for vascular attacks, and gabapentinoids or low-dose tricyclics for neurosensory pain are the evidence-based pharmacologic approaches. Established sensorineural damage at stage 2 or higher is largely irreversible.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness for 5 to 10 days
  • Triggering of a Raynaud-type attack at or near the bite site
  • Worsening of distal ischemia if a practitioner places a leech too distally (the digits and ischemic acral tissue are absolutely off-limits)
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Delay of vibration-exposure cessation and standard pharmacotherapy
Who should not consider this
  • Anyone still working with vibrating tools without exposure cessation
  • Patients with digital ulceration, gangrene, or severe ischemia
  • Patients on anticoagulants or with anemia
  • Patients whose symptoms are better explained by carpal tunnel syndrome or cervical radiculopathy (these must be excluded first)
  • Smokers who have not addressed tobacco use (compounds vasospasm)
  • Patients whose Raynaud attacks are uncontrolled on nifedipine and need rheumatology referral
What to ask your clinician
  • What is my Stockholm Workshop stage, and is the diagnosis confirmed by sensorineural and vascular testing?
  • Have I stopped vibration exposure, and is occupational change feasible?
  • Am I on nifedipine and have other vasoactive options been considered?
  • Have carpal tunnel and cervical radiculopathy been excluded?
  • Where exactly will the leech be placed — confirm it is on warm proximal forearm, not on digits?
  • What is the realistic expected benefit, given that established sensorineural damage is usually irreversible?
When to seek urgent care
  • A finger turning persistently black, purple, or non-blanching white
  • New ulceration or gangrene of any digit
  • Spreading redness, warmth, pus, or red streaks around a bite site
  • Fever above 38.0 C / 100.4 F
  • Bleeding from a bite site lasting more than 24 hours
  • Rapidly progressive numbness or weakness in the arm

What this does NOT mean

  • It does not substitute for removal from vibration exposure, which is the single most important intervention.
  • Leeches are never placed on the digits themselves or on any ischemic acral tissue.
  • It does not reverse established sensorineural damage, which is largely irreversible at stage 2 or higher.
  • Concomitant carpal tunnel syndrome or cervical radiculopathy must be excluded as alternative or additional cause.

Clinical Profile

Category
Vascular
ICD-10
T75.21XA, I73.00, I73.01
Safety tier
Medium

Evidence Summary

Hand-arm vibration syndrome (HAVS) results from chronic occupational exposure to vibrating tools (chainsaws, grinders, jackhammers), producing episodic digital ischemia (vibration-induced Raynaud phenomenon), sensorineural deficits, and musculoskeletal pain. Stockholm Workshop classification stages severity. Evidence-based management is removal from vibration exposure (essential), smoking cessation, cold avoidance, calcium channel blockers (nifedipine) for vascular attacks, and gabapentinoids or low-dose tricyclics for neurosensory pain. There is no curative therapy; progression depends primarily on continued exposure. No clinical study or case report of leech therapy for HAVS or vibration disease was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or Russian-language searches (searched October 2026). The nearest report is an uncontrolled single-centre series from Azerbaijan (Farzali 2025; 181 patients with 11 conditions) that included three patients with Raynaud disease; it did not address vibration-induced disease. A mechanistic rationale of microcirculatory improvement is intuitive but unsupported by clinical evidence.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active deep vein thrombosis (acute phase)
  • Critical limb ischemia (ABI <0.4)
  • Continued vibration exposure (cessation is essential)
  • Digital ulceration or gangrene
  • Placement on digits or ischemic acral tissue (absolute)
  • Severe sensorineural deficit suggesting alternate diagnosis (carpal tunnel, cervical radiculopathy)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.